Author pages are created from data sourced from our academic publisher partnerships and public sources.
Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
- M. Guix, N. M. Granja, +15 authors C. Arteaga
- Journal of clinical oncology : official journal…
- 20 February 2008
PURPOSE To administer the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to patients with operable untreated breast cancer during the immediate preoperative period and to… Expand
Potential use of loss of heterozygosity in pleural effusions of breast cancer metastases using the microsatellite marker of the 16q22.1 region of the CDH1 gene.
- N. M. Granja, S. Ricardo, +4 authors F. Schmitt
- Analytical and quantitative cytology and…
- 1 April 2005
OBJECTIVE To evaluate the presence of allelic loss in 16q22.1, including the locus of E-cadherin, in pleural effusions in breast cancer patients. STUDY DESIGN Molecular analysis of DNA was… Expand
Carcinoma da mama em mulheres jovens: análise da expressão das proteínas P53 e C-erb B--2 e do índice proliferativo
Pelvic exenteration and sphincter preservation in the treatment of soft tissue sarcomas.
- A. Lopes, A. H. O. Poletto, A. Carvalho, E. A. Ribeiro, N. M. Granja, B. M. Rossi
- European journal of surgical oncology : the…
- 1 November 2004
BACKGROUND Pelvic sarcomas are rare and there are very few effective therapeutic alternatives. A complete resection is considered the main factor associated to a good prognosis, which justifies the… Expand
Cancer Therapy : Preclinical Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER 2 Inhibitors against HER 2-Overexpressing Cancer Cells
Purpose: A significant fraction of HER2-overexpressing breast cancers exhibit resistance to the HER2 antibody trastuzumab. Hyperactivity of the phosphatidylinositol 3kinase (PI3K)/AKT pathway confers… Expand